久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra

expresspharmaDecember 22, 2020

Tag: AstraZeneca , DCGI , benralizumab , CT-20 , FASENRA

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Marketing Authorisation) from the Drugs Controller General of India (DCGI) for Benralizumab 30mg/mL solution for injection (Fasenra).

Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

The receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.

Previous:Sosei Heptares and GSK sign collaboration and license pact targeting GI immune disorders

Next:FDA investigates allergic reactions of Pfizer Covid-19 vaccine in US

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service